GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Short Interest

Vertex Pharmaceuticals (BSP:VRTX34) Short Interest


View and export this data going back to 2019. Start your Free Trial

What is Vertex Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Vertex Pharmaceuticals's Short Interest

For the Biotechnology subindustry, Vertex Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vertex Pharmaceuticals's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Short Interest falls into.


Vertex Pharmaceuticals (BSP:VRTX34) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (BSP:VRTX34) » Definitions » Short Interest
Comparable Companies
REGN MRNA BNTX ALNY BGNE BMRN RPRX SRPT INCY UTHR OCSE:NOVO B ASX:CSL XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX OCSE:GMAB SHSE:603392 SZSE:300122 XKRX:028300
Traded in Other Exchanges
VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX:Austria
Address
50 Northern Avenue, Boston, MA, USA, 02210
Website
https://www.vrtx.com
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Vertex Pharmaceuticals (BSP:VRTX34) Headlines

No Headlines